<DOC>
	<DOCNO>NCT02712177</DOCNO>
	<brief_summary>Bexsero™ four component serogroup B meningococcal vaccine ( 4CMenB ) license Europe , Canada , Australia 2014 . Prelicensure study post marketing surveillance data show 4CMenB high reactogenicity especially coadministered infant routine vaccine [ 1-2 ] . While suggests coadministration cause interaction result great risk adverse event follow Immunization ( AEFI ) AEFI 4CMenB dose occur routine vaccine immunization report , underestimate total risk associate immunization separate visit . For financial practical reason , coadministration infant vaccine prefer separate visit . Separate visit may however prefer sum AEFI risk visit significantly small risk coadministration and/or AEFI less severity . The purpose study recalculate risk occurrence severity AEFI coadministration Bexsero™ routine vaccine compare separate injection assess interaction occur co-administration . Investigators also estimate risk recurrence AEFI subsequent immunization 4CMenB ass risk varies separate coadministration routine vaccine . To achieve purpose , investigator perform secondary analysis data three randomize control trial ( clinicaltrials.gov identifier : NCT00657709 , NCT00847145 NCT00721396 ) evaluate 5025 child age 2 14 month 4535 randomize receive 3 4 dos 4CMenB concomitantly alternatively routine vaccination ( DTaP-IPV-HepB/Hib [ Infanrix Hexa™ ] , PCV7 [ Prevenar™ ] MMRV [ Priorix-Tetra™ ] ) [ 1,2 ] .</brief_summary>
	<brief_title>Bexsero™and Routine Infant Vaccines : Effect Coadministration Safety Immunization</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy 2month old infant ( 5589 day , inclusive ) , bear full term pregnancy estimate gestational age ≥ 37 week Parent/legal guardian give write informed consent nature study explain . Main exclusion Criteria : History meningococcal B C vaccine administration ; prior vaccination routine infant vaccine ( Diphtheria , Tetanus , Pertussis , Polio , Haemophilus influenzae type b ( Hib ) , Pneumococcal antigens ) ; Previous ascertain suspected disease cause N. meningitidis ; History severe allergic reaction previous vaccination hypersensitivity vaccine component ; Significant acute chronic infection within previous 7 day axillary temperature major equal to38 degree within previous day ; Antibiotics within 6 day prior enrollment ; Any serious chronic progressive disease ; Known suspect impairment alteration immune system ; Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>14 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>vaccine safety</keyword>
	<keyword>interaction</keyword>
</DOC>